Michael C. Jensen

33.3k citations

254 papers · 20.3k indexed · 11 hit papers · h-index 65

Impact in

Oncology top 0.02%
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
Immunology top 0.1%
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses

Papers in

Oncology 179
- CAR-T cell therapy research 175
Immunology 92
- Immune Cell Function and Interaction 55
- Immunotherapy and Immune Responses 45
- T-cell and B-cell Immunology 16

Co-authors: Stanley R. Riddell Stephen J. Forman Rebecca Gardner Christine E. Brown Daniel W. Lee David Porter Crystal L. Mackall Chrystal U. Louis
Journals: Blood (52 papers)Journal of Financial Economics (17 papers)Molecular Therapy (13 papers)Journal of Clinical Oncology (12 papers)Neuro-Oncology (9 papers)
Partner nations: United States Germany South Africa

In The Last Decade

Michael C. Jensen

238 papers receiving 19.9k citations

Hit Papers

11 papers align trajectories log scale

Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults 2017 · 787 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2017 Blood
2016 Blood
2016 Cancer Immunology Research
2015 Clinical Cancer Research
2014 Cancer Immunology Research
2014 Blood
2012 Blood
2011 Blood
2008 Journal of Clinical Investigation
2008 Blood
2006 Nature Medicine

Peers

Countries citing papers authored by Michael C. Jensen

Since Specialization

Citations

This map shows the geographic impact of Michael C. Jensen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael C. Jensen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael C. Jensen more than expected).

Fields of papers citing papers by Michael C. Jensen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael C. Jensen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael C. Jensen. The network helps show where Michael C. Jensen may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Michael C. Jensen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael C. Jensen Line = papers co-authored together Michael C. Jensen links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	STRIvE-02: A First-in-Human Phase I Study of Systemically Administered B7-H3 Chimeric Antigen Receptor T Cells for Patients With Relapsed/Refractory Solid Tumors Journal of Clinical Oncology ·Navin Pinto, Catherine M. Albert, Mallory Taylor, Haruna Sanke, Ashley Wilson, Wenjun Huang, Jason Wendler, Sowmya Pattabhi, Kristy Seidel, Christopher Brown, Joshua A. Gustafson, Stephanie Rawlings-Rhea, 黄嘉玲, د. مسفر محمد حسن العجمي, Heather H. Gustafson, Rimas J. Orentas, Nicholas A. Vitanza, Rebecca Gardner, Michael C. Jensen, Julie R. Park	2024	14
2	Differential protein-protein interactions underlie signaling mediated by the TCR and a 4-1BB domain–containing CAR Science Signaling ·徐淳, 浜中順一, A. Raeisaenen, Jonathan D. Lautz, Yu‐Jie Zeng, Joshua A. Gustafson, Ashley Wilson, Chenwei Lin, Philip R. Gafken, Michael C. Jensen, Rimas J. Orentas, Stephen Smith	2024	4
3	Rationally Designed Transgene-Encoded Cell-Surface Polypeptide Tag for Multiplexed Programming of CAR T-cell Synthetic Outputs Cancer Immunology Research ·Adam Johnson, Jia Wei, James M. Rosser, Annette Künkele, Cindy A. Chang, 姜润喜, Michael C. Jensen	2021	8
4	CD22 CAR Optimization for Improved in-Human Activity Following Inadequate CD22 CAR Activity in Phase 1 Clinical Trial PLAT-04 Blood ·Corinne Summers, E P Purtell, Colleen Annesley, Jason K. Yokoyama, Nicole M. Arwood, Wenjun Huang, Ashley Wilson, Julie R. Park, Rimas J. Orentas, Michael C. Jensen, Rebecca Gardner	2021	4
5	Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors Clinical Cancer Research ·Ashwini Balakrishnan, Anusha Rajan, Alexander I. Salter, Paula L. Kosasih, Qian Wu, Jenna Voutsinas, Michael C. Jensen, Andreas Plückthun, Stanley R. Riddell	2019	48
6	Preclinical Assessment of CD171-Directed CAR T-cell Adoptive Therapy for Childhood Neuroblastoma: CE7 Epitope Target Safety and Product Manufacturing Feasibility Clinical Cancer Research ·Annette Künkele, Agne Taraseviciute, Laura S. Finn, Adam Johnson, Carolina Berger, Olivia Finney, Cindy A. Chang, Lisa S. Rolczynski, Christopher Brown, Stephanie Mgebroff, Michael Berger, Julie R. Park, Michael C. Jensen	2016	75
7	Preserved Activity of CD20-Specific Chimeric Antigen Receptor–Expressing T Cells in the Presence of Rituximab Cancer Immunology Research ·J. M. Rijnkels, Oliver W. Press, Philip Olsen, Sang Yun Lee, Michael C. Jensen, Ajay K. Gopal, Barbara Pender, Lihua E. Budde, Hassan Mabchour, Damian J. Green, David G. Maloney, Stanley R. Riddell, Brian G. Till	2016	22
8	T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells Cancer Immunology Research ·Eugenia Zah, Meng-Yin Lin, Anne Silva-Benedict, Michael C. Jensen, Yvonne Y. Chen Hit paper breakdown →	2016	462
9	CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells Clinical Cancer Research ·Xiuli Wang, ChingLam W. Wong, Ryan Urak, Armen Mardiros, Lihua E. Budde, Wen-Chung Chang, Sandra H. Thomas, Christine E. Brown, Corinna La Rosa, Don J. Diamond, Michael C. Jensen, Ryotaro Nakamura, John A. Zaia, Stephen J. Forman	2015	52
10	Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma Clinical Cancer Research ·Christine E. Brown, Behnam Badie, Michael E. Barish, Lihong Weng, Julie R. Ostberg, Wen-Chung Chang, Araceli Naranjo, Renate Starr, Jamie R. Wagner, Christine L. Wright, Yubo Zhai, James R. Bading, Julie A. Ressler, Jana Portnow, Massimo D’Apuzzo, Stephen J. Forman, Michael C. Jensen Hit paper breakdown →	2015	592
11	Functional Tuning of CARs Reveals Signaling Threshold above Which CD8+ CTL Antitumor Potency Is Attenuated due to Cell Fas–FasL-Dependent AICD Cancer Immunology Research ·Annette Künkele, Adam Johnson, Lisa S. Rolczynski, Cindy A. Chang, Virginia J. Hoglund, Karen S. Kelly‐Spratt, Michael C. Jensen	2015	130
12	The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity Cancer Immunology Research ·Michael Hudecek, Daniel Sommermeyer, Paula L. Kosasih, Anne Silva-Benedict, Lingfeng Liu, Christoph Rader, Michael C. Jensen, Stanley R. Riddell Hit paper breakdown →	2014	406
13	Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells Clinical Cancer Research ·Michael Hudecek, Maria Teresa Lupo Stanghellini, Paula L. Kosasih, Daniel Sommermeyer, Michael C. Jensen, Christoph Rader, Stanley R. Riddell	2013	424
14	Stem-like Tumor-Initiating Cells Isolated from IL13Rα2 Expressing Gliomas Are Targeted and Killed by IL13-Zetakine–Redirected T Cells Clinical Cancer Research ·Christine E. Brown, Renate Starr, Brenda Aguilar, Bárbara Botelho Barboza, Catalina Martínez, Massimo D’Apuzzo, Michael E. Barish, Stephen J. Forman, Michael C. Jensen	2012	185
15	CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results Blood ·Brian G. Till, Michael C. Jensen, Jinjuan Wang, Xiaojun Qian, Ajay K. Gopal, David G. Maloney, Catherine Lindgren, Yukang Lin, John M. Pagel, Lihua E. Budde, Andrew Raubitschek, Stephen J. Forman, Philip D. Greenberg, Stanley R. Riddell, Oliver W. Press Hit paper breakdown →	2012	431
16	Induction of Anti-Glioma Natural Killer Cell Response following Multiple Low-Dose Intracerebral CpG Therapy Clinical Cancer Research ·Darya Alizadeh, Leying Zhang, Christine E. Brown, Heather F. Harcourt, Michael C. Jensen, Behnam Badie	2010	64
17	Targeting STAT3 in Adoptively Transferred T Cells Promotes Their In Vivo Expansion and Antitumor Effects Cancer Research ·Maciej Kujawski, Chunyan Zhang, Andreas Herrmann, Karen L. Reckamp, Anna Scuto, Michael C. Jensen, Jiehui Deng, Stephen J. Forman, Robert A. Figlin, Hua Yu	2010	99
18	Recognition and Killing of Brain Tumor Stem-Like Initiating Cells by CD8+ Cytolytic T Cells Cancer Research ·Christine E. Brown, Renate Starr, Catalina Martínez, Brenda Aguilar, Massimo D’Apuzzo, Иван Тодоров, Serge Besner, Behnam Badie, Michael Hudecek, Stanley R. Riddell, Michael C. Jensen	2009	113
19	Combining Adoptive Cellular and Immunocytokine Therapies to Improve Treatment of B-Lineage Malignancy Cancer Research ·Harjeet Singh, Lisa Marie Serrano, Maryam M. AL-Mousawi, Simon Olivares, George McNamara, David Smith, Zaid Al‐Kadhimi, Stephen J. Forman, Stephen D. Gillies, Michael C. Jensen, David Colcher, Andrew Raubitschek, Laurence J.N. Cooper	2007	31
20	Restoration of CD28 Expression in CD28− CD8 + Memory Effector T Cells Reconstitutes Antigen-induced IL-2 Production The Journal of Experimental Medicine ·Max S. Topp, Stanley R. Riddell, Yoshiki Akatsuka, Michael C. Jensen, Joseph N. Blattman, Philip D. Greenberg	2003	109

About Michael C. Jensen

Michael C. Jensen is a scholar working on Oncology, Immunology, Genetics, Genetics and Molecular Biology, having authored 254 papers that have together received 20.3k indexed citations. Recurring topics across this work include CAR-T cell therapy research (175 papers), Immune Cell Function and Interaction (55 papers), Immunotherapy and Immune Responses (45 papers), Virus-based gene therapy research (43 papers), Nanowire Synthesis and Applications (21 papers), Viral Infectious Diseases and Gene Expression in Insects (17 papers), T-cell and B-cell Immunology (16 papers) and Cytomegalovirus and herpesvirus research (13 papers). The work is most often cited by research in Oncology (15.4k citations), Immunology (6.7k citations), Genetics (4.8k citations), Genetics (1.3k citations) and Biomedical Engineering (4.6k citations). Michael C. Jensen has collaborated with scholars based in United States, Germany and South Africa. Frequent co-authors include Stanley R. Riddell, Stephen J. Forman, Rebecca Gardner, Christine E. Brown, Daniel W. Lee, David Porter, Crystal L. Mackall, Chrystal U. Louis, Nabil Ahmed and Stephan A. Grupp. Their work appears in journals such as Blood, Journal of Financial Economics, Molecular Therapy, Journal of Clinical Oncology and Neuro-Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact